The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1584
ISSUE1584
November 4, 2019
Drugs for Type 2 Diabetes
| Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Drugs for Type 2 Diabetes
November 4, 2019 (Issue: 1584)
Diet, exercise, and weight loss can improve glycemic
control, but almost all patients with type 2 diabetes
eventually require drug therapy. Treating to a glycated
hemoglobin (A1C) concentration of...more
- American Diabetes Association. Professional practice committee for the standards of medical care in diabetes – 2019. Diabetes Care 2019; 42:(Suppl 1).
- AJ Garber et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm – 2019 executive summary. Endocr Pract 2019; 25:69.
- E Ferrannini. The target of metformin in type 2 diabetes. N Engl J Med 2014; 371:1547.
- JB Buse et al. The primary glucose-lowering effect of metformin resides in the gut, not the circulation: results from short-term pharmacokinetic and 12-week dose-ranging studies. Diabetes Care 2016; 39:198.
- RR Holman et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359:1577.
- FDA Drug Safety Communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function. Available at: www.fda. gov/drugs/drugsafety/ucm493244.htm. Accessed October 23, 2019.
- CL Roumie et al. Association of treatment with metformin vs sulfonylurea with major adverse cardiovascular events among patients with diabetes and reduced kidney function. JAMA 2019; 322:1167.
- MJ Crowley et al. Clinical outcomes of metformin use in populations with chronic kidney disease, congestive heart failure, or chronic liver disease: a systematic review. Ann Intern Med 2017; 166:191.
- Canagliflozin (Invokana) for type 2 diabetes. Med Lett Drugs Ther 2013; 55:37.
- B Neal et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377:644.
- V Perkovic et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380;2295.
- Dapagliflozin (Farxiga) for type 2 diabetes. Med Lett Drugs Ther 2014; 56:13.
- SD Wiviott et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019; 380:347.
- JJV McMurray et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. Sept 2019 (epub).
- Empagliflozin (Jardiance) for diabetes. Med Lett Drugs Ther 2014; 56:99.
- B Zinman et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373:2117.
- C Wanner et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375:323.
- SGLT2 inhibitors and renal function. Med Lett Drugs Ther 2016; 58:91.
- C Wanner et al. Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. Circulation 2018; 137:119.
- Ertugliflozin for type 2 diabetes. Med Lett Drugs Ther 2018; 60:70.
- JA Udell et al. Cardiovascular outcomes and risks after initiation of a sodium glucose cotransporter 2 inhibitor: results from the EASEL population-based cohort study (evidence for cardiovascular outcomes with sodium glucose cotransporter 2 inhibitors in the real world). Circulation 2018; 137:1450.
- TA Zelniker et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019; 393:31.
- Two new GLP-1 receptor agonists for diabetes. Med Lett Drugs Ther 2014; 56:109.
- KC Ferdinand et al. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events. Cardiovasc Diabetol 2016; 15:38.
- HC Gerstein et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019; 394:121.
- HC Gerstein et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet 2019; 394:131.
- Exenatide (Byetta) for type 2 diabetes. Med Lett Drugs Ther 2005; 47:45.
- Extended-release exenatide (Bydureon) for type 2 diabetes. Med Lett Drugs Ther 2012; 54:21.
- RR Holman et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2017; 377:1228.
- WV Tamborlane et al. Liraglutide in children and adolescents with type 2 diabetes. N Engl J Med 2019; 381:637.
- SP Marso et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375:311.
- JFE Mann et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 2017; 377:839.
- Lixisenatide for type 2 diabetes. Med Lett Drugs Ther 2017; 59:19.
- MA Pfeffer et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015; 373:2247.
- MHA Muskiet et al. Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 2018; 6:859.
- Semaglutide (Ozempic) - another injectable GLP-1 receptor agonist for type 2 diabetes. Med Lett Drugs Ther 2018; 60:19.
- Oral semaglutide (Rybelsus) for type 2 diabetes. Med Lett Drugs Ther 2019; 61:166.
- SP Marso et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016; 375:1834.
- R Pratley et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet 2019; 394:39.
- VR Aroda et al. PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care 2019; 42:1724.
- HW Rodbard et al. Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial. Diabetes Care 2019 Sep 17 (epub).
- J Rosenstock et al. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial. JAMA 2019; 321:1466.
- O Mosenzon et al. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. Lancet Diabetes Endocrinol 2019; 7:515.
- TR Pieber et al. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial. Lancet Diabetes Endocrinol 2019; 7:528.
- B Zinman et al. Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PIONEER 8 Trial. Diabetes Care 2019 Sep 17 (epub).
- M Husain et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019; 381:841.
- SL Kristensen et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 2019; 7:776.
- PC Butler et al. A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe? Diabetes Care 2013; 36:2118.
- AG Egan et al. Pancreatic safety of incretin-based drugs–FDA and EMA assessment. N Engl J Med 2014; 370:794.
- Alogliptin (Nesina) for type 2 diabetes. Med Lett Drugs Ther 2013; 55:41.
- Linagliptin (Tradjenta) – a new DPP-4 inhibitor for type 2 diabetes. Med Lett Drugs Ther 2011; 53:49.
- Saxagliptin (Onglyza) for type 2 diabetes. Med Lett Drugs Ther 2009; 51:85.
- Sitagliptin (Januvia) for type 2 diabetes. Med Lett Drugs Ther 2007; 49:1.
- SL Zheng et al. Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis. JAMA 2018; 319:1580.
- FDA Drug Safety Communication: FDA adds warnings about heart failure risk to labels of type 2 diabetes medicines containing saxagliptin and alogliptin. Available at: www.fda.gov. Accessed October 24, 2019.
- BM Scirica et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369:1317.
- WB White et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369:1327.
- JB Green et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015; 373:232.
- DK McGuire et al. Linagliptin effects on heart failure and related outcomes in individuals with type 2 diabetes mellitus at high cardiovascular and renal risk in CARMELINA. Circulation 2018; 139:351.
- VP Sanon et al. Play of chance versus concerns regarding dipeptidyl peptidase-4 inhibitors: heart failure and diabetes. Clin Diabetes 2014; 32:121.
- KB Filion and S Suissa. DPP-4 inhibitors and heart failure: some reassurance, some uncertainty. Diabetes Care 2016; 39:735.
- KB Filion et al. A multicenter observational study of incretin-based drugs and heart failure. N Engl J Med 2016: 374:1145.
- D Varvaki Rados et al. The association between sulfonylurea use and all-cause and cardiovascular mortality: a meta-analysis with trial sequential analysis of randomized clinical trials. PLoS Med 2016; 13:e1001992.
- DJ Wexler. Sulfonylureas and cardiovascular safety: the final verdict. JAMA 2019; 322:1147.
- J Rosenstock et al. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial. JAMA 2019; 322:1155.
- J Rosenstock et al. Effect of linagliptin vs placebo on major cardiovascular outcomes in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA 2019; 321:69.
- AV Hernandez et al. Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials. Am J Cardiovasc Drugs 2011; 11:115.
- KW Mahaffey et al. Results of a reevaluation of cardiovascular outcomes in the RECORD trial. Am Heart J 2013; 166:240.
- In brief: Rosiglitazone (Avandia) unbound. Med Lett Drugs Ther 2014; 56:12.
- In brief: a new indication for colesevelam (Welchol). Med Lett Drugs Ther 2008; 50:33.
- Insulins for type 2 diabetes. Med Lett Drugs Ther 2019; 61:65.
- KC Bishop et al. Pharmacologic treatment of diabetes in pregnancy. Obstet Gynecol Surv 2019; 74:289.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Drugs for Type 2 Diabetes
Article code: 1584a
Article code: 1584a
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.